BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGarry ME, McColley SA. Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. Ann Am Thorac Soc 2016;13:1721-5. [PMID: 27410177 DOI: 10.1513/AnnalsATS.201603-192BC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Taha B, Winston G, Tosi U, Hartley B, Hoffman C, Dahmane N, Mason CE, Greenfield JP. Missing diversity in brain tumor trials. Neurooncol Adv 2020;2:vdaa059. [PMID: 32642711 DOI: 10.1093/noajnl/vdaa059] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 McGarry ME, Williams WA 2nd, McColley SA. The demographics of adverse outcomes in cystic fibrosis. Pediatr Pulmonol 2019;54 Suppl 3:S74-83. [PMID: 31715087 DOI: 10.1002/ppul.24434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Sholle ET, Pinheiro LC, Adekkanattu P, Davila MA, Johnson SB, Pathak J, Sinha S, Li C, Lubansky SA, Safford MM, Campion TR. Underserved populations with missing race ethnicity data differ significantly from those with structured race/ethnicity documentation. J Am Med Inform Assoc 2019;26:722-9. [PMID: 31329882 DOI: 10.1093/jamia/ocz040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
5 McGarry ME, Huang CY, Nielson DW, Ly NP. Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States. J Cyst Fibros 2021;20:424-31. [PMID: 33162303 DOI: 10.1016/j.jcf.2020.10.002] [Reference Citation Analysis]
6 Sethi S, Kumar A, Mandal A, Shaikh M, Hall CA, Kirk JMW, Moss P, Brookes MJ, Basu S. The UPTAKE study: implications for the future of COVID-19 vaccination trial recruitment in UK and beyond. Trials 2021;22:296. [PMID: 33879208 DOI: 10.1186/s13063-021-05250-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ding J, Zhou Y, Khan MS, Sy RN, Khosa F. Representation of sex, race, and ethnicity in pivotal clinical trials for dermatological drugs. Int J Womens Dermatol 2021;7:428-34. [PMID: 34621955 DOI: 10.1016/j.ijwd.2021.02.007] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Asubiaro TV, Shaik H. Sub-Saharan African Countries‘ COVID-19 Research: An analysis of the External and Internal Contributions, Collaboration Patterns and Funding Sources. Open Information Science 2021;5:263-77. [DOI: 10.1515/opis-2020-0125] [Reference Citation Analysis]
9 Shemie G, Nguyen MT, Wallenburg J, Ratjen F, Knoppers BM. The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada. J Pers Med 2021;11:382. [PMID: 34067090 DOI: 10.3390/jpm11050382] [Reference Citation Analysis]
10 McGarry ME, McColley SA. Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. Ann Am Thorac Soc 2016;13:1721-5. [PMID: 27410177 DOI: 10.1513/AnnalsATS.201603-192BC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chung A, Seixas A, Williams N, Senathirajah Y, Robbins R, Newsome Garcia V, Ravenell J, Jean-Louis G. Development of "Advancing People of Color in Clinical Trials Now!": Web-Based Randomized Controlled Trial Protocol. JMIR Res Protoc 2020;9:e17589. [PMID: 32673274 DOI: 10.2196/17589] [Reference Citation Analysis]
12 Zeiger AM, McGarry ME, Mak ACY, Medina V, Salazar S, Eng C, Liu AK, Oh SS, Nuckton TJ, Jain D, Blackwell TW, Kang HM, Abecasis G, Oñate LC, Seibold MA, Burchard EG, Rodriguez-Santana J. Identification of CFTR variants in Latino patients with cystic fibrosis from the Dominican Republic and Puerto Rico. Pediatr Pulmonol 2020;55:533-40. [PMID: 31665830 DOI: 10.1002/ppul.24549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Park JK, Shrivastava A, Zhang C, Pollok BA, Finkbeiner WE, Gibb ER, Ly NP, Illek B. Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models. Front Pediatr 2020;8:536. [PMID: 33014932 DOI: 10.3389/fped.2020.00536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 McGarry ME, Neuhaus JM, Nielson DW, Burchard E, Ly NP. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis. Pediatr Pulmonol 2017;52:1550-7. [PMID: 29082671 DOI: 10.1002/ppul.23884] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]